- Home
- OLED vs ELVN Comparison
OLED vs ELVN Comparison
Compare OLED & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLED | ELVN |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.2B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OLED | ELVN |
|---|---|---|
| Price | $82.64 | $59.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $125.00 | $43.40 |
| AVG Volume (30 Days) | 675.5K | ★ 829.1K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 9.25 | 3.17 |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $650,611,000.00 | N/A |
| Revenue This Year | $5.88 | N/A |
| Revenue Next Year | $10.36 | N/A |
| P/E Ratio | $45.91 | ★ N/A |
| Revenue Growth | ★ 0.45 | N/A |
| 52 Week Low | $76.42 | $14.79 |
| 52 Week High | $153.38 | $62.32 |
Technical Indicators
Market Signals| Indicator | OLED | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.87 | 57.65 |
| Support Level | $77.02 | $56.69 |
| Resistance Level | $95.90 | $62.16 |
| Average True Range (ATR) | 3.01 | 2.05 |
| MACD | -0.69 | -0.47 |
| Stochastic Oscillator | 8.65 | 57.41 |
Price Performance
Historical ComparisonAbout OLED Universal Display Corporation
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. The large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.